AMGN:NGS-Amgen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 186.19

Change

+2.24 (+1.22)%

Market Cap

USD 123.20B

Volume

2.54M

Yahoo Analyst Target

USD 195.30 (4.89%)

STA Analyst Target

USD 195.33 (4.91%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The Company's business segment is human therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-06-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
GILD Gilead Sciences Inc.

+1.88 (+2.72%)

USD 92.24B
BIIB Biogen Inc.

+2.92 (+1.01%)

USD 61.62B
CELG Celgene Corporation

+1.71 (+2.20%)

USD 56.15B
SHPG Shire plc

-3.07 (-1.92%)

USD 47.83B
VRTX Vertex Pharmaceuticals Incorpo..

+2.81 (+1.85%)

USD 39.37B
REGN Regeneron Pharmaceuticals Inc.

+11.46 (+3.63%)

USD 35.28B
ALXN Alexion Pharmaceuticals Inc.

+3.24 (+2.73%)

USD 27.13B
BMRN BioMarin Pharmaceutical Inc.

+0.04 (+0.04%)

USD 16.90B
INCY Incyte Corporation

+0.96 (+1.33%)

USD 15.47B
GRFS Grifols S.A.

-0.17 (-0.75%)

USD 15.45B

ETFs Containing AMGN

BBH VanEck Vectors Biotech ET.. 11.78 % 0.35 %

+0.94 (+0.78%)

USD 0.43B
IBB iShares Nasdaq Biotechnol.. 7.89 % 0.00 %

+1.61 (+1.46%)

USD 9.06B
BIB ProShares Ultra Nasdaq Bi.. 6.93 % 0.95 %

+1.73 (+2.99%)

USD 0.37B
UBIO Proshares UltraPro Nasdaq.. 6.14 % 0.95 %

+1.46 (+4.31%)

USD 0.04B
LIFE.B:CA Evolve Global Healthcare .. 5.30 % 0.00 %

N/A

CAD 0.49M
LIFE:CA Evolve Global Healthcare .. 5.30 % 0.00 %

N/A

CAD 0.93M
PJP Invesco Dynamic Pharmaceu.. 5.02 % 0.56 %

+0.60 (+0.89%)

USD 0.55B
HHL:CA Harvest Healthcare Leader.. 5.02 % 1.24 %

N/A

CAD 0.26B
PBE Invesco Dynamic Biotech &.. 4.87 % 0.58 %

+0.47 (+0.86%)

USD 0.26B
XLV SPDR Select Sector Fund -.. 3.74 % 0.14 %

+0.22 (+0.26%)

USD 15.93B
PILL Direxion Daily Pharmaceut.. 3.70 % 0.00 %

+0.95 (+3.25%)

USD 4.50M
JHMH John Hancock Multifactor .. 3.68 % 0.50 %

+0.15 (+0.47%)

USD 0.04B
SHE SPDR Series Trust SSGA Ge.. 3.51 % 0.20 %

-0.23 (-0.31%)

USD 0.33B
IYH iShares U.S. Healthcare 3.51 % 0.44 %

+0.40 (+0.22%)

USD 1.89B
RXL ProShares Ultra Health Ca.. 3.29 % 0.95 %

+0.32 (+0.35%)

USD 0.10B
FHLC Fidelity MSCI Health Care.. 3.22 % 0.08 %

+0.15 (+0.36%)

USD 1.18B
VHT Vanguard Health Care 3.16 % 0.10 %

+0.54 (+0.33%)

USD 7.45B
LNGR Global X Longevity Themat.. 3.02 % 0.52 %

-0.07 (-0.33%)

N/A
HAU:CA Horizons Active US Divide.. 2.88 % 0.80 %

N/A

CAD 7.20M
IXJ iShares Global Healthcare 2.56 % 0.48 %

-0.48 (-0.84%)

USD 1.55B
FTHI First Trust BuyWrite Inco.. 1.82 % 0.85 %

+0.03 (+0.13%)

USD 0.06B
FTLB First Trust Hedged BuyWri.. 1.80 % 0.85 %

N/A

USD 9.08M
ONEQ Fidelity Nasdaq Composite.. 0.00 % 0.21 %

-0.71 (-0.23%)

USD 1.61B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.07% 56% F 59% F
Dividend Return 1.52% 50% F 73% C
Total Return 8.59% 57% F 61% D-
Trailing 12 Months  
Capital Gain 12.78% 53% F 56% F
Dividend Return 2.99% 57% F 70% C-
Total Return 15.77% 55% F 58% F
Trailing 5 Years  
Capital Gain 87.73% 69% D+ 63% D
Dividend Return 17.93% 56% F 71% C-
Total Return 105.66% 71% C- 66% D
Average Annual (5 Year Horizon)  
Capital Gain 12.78% 57% F 63% D
Dividend Return 15.19% 61% D- 65% D
Total Return 2.42% 40% F 62% D-
Risk Return Profile  
Volatility (Standard Deviation) 15.42% 92% A- 75% C
Risk Adjusted Return 98.50% 99% A+ 84% B
Market Capitalization 107.37B 100% A+ 100% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 58.74 1% F 8% F
Price/Book Ratio 4.92 46% F 25% F
Price / Cash Flow Ratio 3.01 8% F 42% F
Price/Free Cash Flow Ratio 12.18 7% F 41% F
Management Effectiveness  
Return on Equity 8.47% 84% B 65% D
Return on Invested Capital 16.86% 90% A- 84% B
Return on Assets 2.85% 90% A- 70% C-
Debt to Equity Ratio 147.50% 11% F 16% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

AMGN:NGS-Amgen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 186.19

Change

+2.24 (+1.22)%

Market Cap

USD 123.20B

Volume

2.54M

Yahoo Analyst Target

USD 195.30 (4.89%)

STA Analyst Target

USD 195.33 (4.91%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-06-19